News Geron Corporation

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
3.45 ^USD	-5.22%		+3.60%	+63.51%

Mar. 19	Geron Prices $150 Million Offering of Shares, Pre-Funded Warrants	MT
Mar. 15	Sector Update: Health Care Stocks Ease Late Afternoon	MT

Geron to Participate at Upcoming Investor Conferences in April	Apr. 03	BU
Geron : Fiscal Year 2023 Annual Report	Mar. 28	PU
Geron : Fiscal Year 2024 Proxy	Mar. 28	PU
Geron Prices $150 Million Offering of Shares, Pre-Funded Warrants	Mar. 19	MT
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants	Mar. 19	BU
Geron : Risk Factor Summary - Form 8-K	Mar. 19	PU
Sector Update: Health Care Stocks Ease Late Afternoon	Mar. 15	MT
Sector Update: Health Care Stocks Softer Friday Afternoon	Mar. 15	MT
Sector Update: Health Care	Mar. 15	MT
Needham Adjusts Geron's Price Target to $5 From $4, Maintains Buy Rating	Mar. 15	MT
Top Midday Gainers	Mar. 15	MT
Geron Shares Soar on Positive FDA Advisory Panel's Vote on Imetelstat for Blood Disorder	Mar. 15	MT
Goldman Sachs Adjusts Price Target on Geron to $5 From $4, Keeps Buy Rating	Mar. 15	MT
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit, Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS	Mar. 15	AQ
Sector Update: Health Care Stocks Edge Higher Premarket Friday	Mar. 15	MT
Sector Update: Health Care	Mar. 15	MT
Investors Turn Cautious Ahead of Next Week's Fed Meeting, Stifling US Equity Futures Pre-Bell	Mar. 15	MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Friday as Rate Cut Hopes Wane	Mar. 15	MT
Top Premarket Gainers	Mar. 15	MT
Geron Gets Favorable Vote From FDA Advisory Committee on Imetelstat for Blood Disorder	Mar. 14	MT

No results for this search